JACC: Basic to Translational Science (Jun 2019)

Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction

  • Wei Wang, MD, PhD,
  • Liyan Zhang, PhD,
  • Pavan K. Battiprolu, PhD,
  • Arata Fukushima, MD, PhD,
  • Khanh Nguyen, BS,
  • Kenneth Milner, BS,
  • Abhishek Gupta, PhD,
  • Tariq Altamimi, PhD,
  • Nikole Byrne, BS,
  • Jun Mori, MD, PhD,
  • Osama Abo Alrob, PhD,
  • Cory Wagg,
  • Natasha Fillmore, PhD,
  • Shao-hua Wang, MD, PhD,
  • Dongming M. Liu, BS,
  • Angela Fu, BS,
  • Jenny Yinglin Lu, BS,
  • Mary Chaves, MS,
  • Alykhan Motani, PhD,
  • John R. Ussher, PhD,
  • Jeff D. Reagan, PhD,
  • Jason R.B. Dyck, PhD,
  • Gary D. Lopaschuk, PhD

Journal volume & issue
Vol. 4, no. 3
pp. 385 – 400

Abstract

Read online

Summary: Alterations in cardiac energy metabolism after a myocardial infarction contribute to the severity of heart failure (HF). Although fatty acid oxidation can be impaired in HF, it is unclear if stimulating fatty acid oxidation is a desirable approach to treat HF. Both immediate and chronic malonyl coenzyme A decarboxylase inhibition, which decreases fatty acid oxidation, improved cardiac function through enhancing cardiac efficiency in a post–myocardial infarction rat that underwent permanent left anterior descending coronary artery ligation. The beneficial effects of MCD inhibition were attributed to a decrease in proton production due to an improved coupling between glycolysis and glucose oxidation. Key Words: fatty acid oxidation, heart failure, glucose oxidation, uncoupling of glycolysis